Nuo Therapeutics CEO exercises options, gets new grant
Rhea-AI Filing Summary
Nuo Therapeutics CEO/CFO David Emerson Jorden exercised 162,500 stock options at $1.00 on June 30, 2026 through a net exercise that delivered 1,608 common shares after 160,892 shares were withheld at $1.01 for exercise price and taxes. He also received a grant of 125,000 options at $1.01 on June 29, 2026, expiring June 29, 2036, with one third exercisable as of June 30, 2027 and the balance vesting quarterly over the following two years. Following these updates and a 25,381-share correction from a prior report, he directly holds 2,061,227 common shares and 125,000 options.
Positive
- None.
Negative
- None.
Insider Trade Summary
Net Buyer: 1,608 shares
Net Buy
4 txns
Insider
JORDEN DAVID EMERSON
Role
CEO/CFO
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Option to purchase common stock | 162,500 | $0.00 | $0.00 |
| Exercise | Common Stock | 162,500 | $1.00 | $163K |
| Exercise Price or Tax Liability | Common Stock | 160,892 | $1.01 | $163K |
| Grant/Award | Option to purchase common stock | 125,000 | $0.00 | $0.00 |
Holdings After Transaction:
Option to purchase common stock — 125,000 shares (Direct);
Common Stock — 2,061,227 shares (Direct)
Footnotes (4)
- F1. Represents a net exercise of outstanding stock options. The reporting person received 1,608 shares of common stock on the net exercise of option to purchase 162,500 shares of common stock. The issuer withheld 160,892 shares of common stock underlying the option for payment of the exercise price using the closing price of $1.01.
- F2. Reflects an adjustment of 25,381 shares since the Reporting Person's most recent Form 4 filed June 5, 2026 to correct the amount of securities beneficially owned as a result of the transaction reported in that Form 4.
- F3. 62,500 options exercisable on 07/01/2016, 50,000 options exercisable on 03/31/2017, and 50,000 options exercisable on 12/31/2017.
- F4. One third of the options are exercisable as of June 30, 2027 and the balance vest quarterly over the subsequent two years.
Key Figures
Options exercised: 162,500 shares
Shares withheld for taxes: 160,892 shares
Net shares received: 1,608 shares
+4 more
7 metrics
Options exercised
162,500 shares
Options to purchase common stock exercised on June 30, 2026 at $1.00 per share
Shares withheld for taxes
160,892 shares
Common shares withheld on June 30, 2026 using the closing price of $1.01
Net shares received
1,608 shares
Common shares received from the net exercise of 162,500 stock options
New options granted
125,000 options
Options granted June 29, 2026 with a $1.01 exercise price, expiring June 29, 2036
Common stock holdings
2,061,227 shares
Direct common stock beneficially owned after the reported transactions
Option holdings
125,000 options
Direct options to purchase common stock outstanding after the grant and exercise
Beneficial ownership adjustment
25,381 shares
Correction to prior Form 4 beneficial ownership from June 5, 2026
Key Terms
net exercise, beneficially owned, closing price, vest quarterly
4 terms
net exercise financial
"Represents a net exercise of outstanding stock options."
A net exercise is a way to convert stock options into shares without paying cash up front: instead of handing over money to buy the optioned shares, the holder receives only the number of shares equal to the option’s value after the company withholds a portion of shares to cover the exercise price and taxes. It matters to investors because it changes how many new shares are issued, affects dilution of existing shareholders, and alters company cash flow compared with a cash exercise.
beneficially owned financial
"to correct the amount of securities beneficially owned as a result of the transaction"
Beneficially owned describes securities or assets where a person has the economic rights and control—such as the right to receive dividends and to direct voting—even if legal title is held in another name. Think of it like having the keys and using a car that’s registered to someone else: you get the benefits and make decisions. Investors care because beneficial ownership reveals who truly controls value and voting power, affecting corporate decisions and takeover dynamics.
closing price financial
"for payment of the exercise price using the closing price of $1.01"
vest quarterly financial
"One third of the options are exercisable as of June 30, 2027 and the balance vest quarterly"
FAQ
What insider transactions did Nuo Therapeutics (AURX) report for its CEO?
Nuo Therapeutics reported that CEO/CFO David Emerson Jorden exercised 162,500 stock options at $1.00 per share using a net exercise, had 160,892 shares withheld to cover costs, received 1,608 common shares, and was granted a new 125,000-option award in June 2026.
How many options did the Nuo Therapeutics (AURX) CEO exercise and what were the tax withholdings?
He exercised 162,500 stock options at $1.00 per share, with the issuer withholding 160,892 common shares at a closing price of $1.01 to satisfy the exercise price and tax obligations, resulting in 1,608 net shares of common stock delivered.
What are the terms of the new stock option grant at Nuo Therapeutics (AURX)?
On June 29, 2026, the CEO received a 125,000-option grant with a $1.01 exercise price, expiring June 29, 2036. One third of these options are exercisable as of June 30, 2027, with the remaining options vesting quarterly over the subsequent two years.
AI-generated analysis. How Rhea-AI works. Not financial advice.
